Method for simultaneously expressing bFGF (basic fibroblast growth factor) and EGF (epidermal growth factor) in bombyx mori and facilitating rapid purification of protein

By fusing bFGF and EGF genes in silkworms and constructing recombinant baculovirus, combining heparin affinity chromatography and TEV enzyme cleavage, the problem of difficulty in purification of recombinant proteins in silkworms was solved, and efficient expression and rapid purification of bFGF and EGF were achieved. , reduces production costs.

CN118955682APending Publication Date: 2024-11-15ZHEJIANG UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411199410.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-29
Publication Date
2024-11-15

AI Technical Summary

Technical Problem

In the prior art, it is difficult to isolate and purify recombinant bFGF and EGF proteins from silkworms, resulting in low purification efficiency and high cost of recombinant proteins.

Method used

The bFGF and EGF genes were fused together through gene fusion design, TEV cleavage sites were set, recombinant baculovirus was constructed, and efficient expression was achieved in silkworms, and rapid purification was performed using heparin affinity chromatography and TEV cleavage.

Benefits of technology

The purification efficiency of recombinant proteins is significantly improved, production costs are reduced, the rapid purification of bFGF and EGF is achieved, and the working efficiency of silkworm bioreactors is improved.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118955682A_ABST
    Figure CN118955682A_ABST
Patent Text Reader

Abstract

The invention discloses a method for simultaneously expressing bFGF (basic fibroblast growth factor) and EGF (epidermal growth factor) in bombyx mori and facilitating rapid purification of protein. According to the method, gene fusion and gene synthesis technologies are utilized, baculovirus coding protein codon preference is utilized, two genes of bFGF and EGF are re-optimized and designed, the two genes are fused, a TEV restriction enzyme cutting site is arranged between the two genes, then a bombyx mori baculovirus expression system is utilized to construct recombinant baculovirus, and the recombinant baculovirus is obtained. The bFGF-EGF fusion protein is expressed in bombyx mori cells and bombyx mori, the protein is rapidly separated and purified by using a heparin affinity chromatography column, finally the two proteins are separated by using TEV enzyme, and effective separation of the two proteins is realized after the two proteins pass through the affinity chromatography column again. According to the method disclosed by the invention, the purification efficiency of the recombinant protein is remarkably improved, the production cost of the recombinant bFGF and EGF is greatly reduced, and a remarkably innovative technology is provided for large-scale production and medical application of the recombinant bFGF and EGF.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of molecular biotechnology, and in particular relates to a method for simultaneously expressing bFGF and EGF in silkworms and facilitating rapid protein purification. Background Art

[0002] Human basic fibroblast growth factor (bFGF) and human epidermal growth factor (EGF) are two growth factors with multiple biological functions such as regulating and promoting cell growth and proliferation. bFGF can be used clinically to treat surgical trauma (burns, scalds, etc.), skin ulcers, corneal damage, tissue repair, etc., while EGF can promote epidermal cell proliferation, differentiation and migration, thereby accelerating cell metabolism, achieving the purpose of moisturizing the skin and delaying aging. Therefore, it is loved by the cosmetics and medical beauty industries and is called the "beauty factor".

[0003] At present, bFGF and EGF are obtained by genetic engineering methods, using in vitro expression systems to express recombinant proteins in prokaryotes (such as Escherichia coli) and eukaryotic cells (yeast cells, insect cells and human cells, etc.). The use of the silkworm baculovirus expression system to construct recombinant baculovirus to express recombinant proteins has the advantages of short cycle, low cost and good recombinant protein activity and is widely praised. However, since silkworm cells themselves contain a large amount of protein, it is very difficult to separate and purify recombinant proteins from silkworms. Summary of the invention

[0004] The purpose of the present invention is to provide a method for simultaneously expressing bFGF and EGF in silkworms and facilitating rapid protein purification, aiming to achieve both simultaneous expression of two growth factors in silkworms and rapid purification of recombinant proteins, thereby significantly improving the working efficiency of silkworm bioreactors.

[0005] The present invention fuses two target genes together through a gene fusion method, sets a TEV restriction site in the middle, designs bFGF-Tev-EGF that can be efficiently expressed in silkworm cells, constructs corresponding recombinant baculovirus, achieves efficient simultaneous expression of bFGF and EGF in silkworms, and achieves rapid purification of recombinant proteins, effectively solving the problem of difficulty in separating recombinant proteins from silkworms in the prior art.

[0006] In order to achieve the above-mentioned invention object, the technical solution adopted by the present invention is as follows:

[0007] (1) Re-optimization design of two genes, human basic fibroblast growth factor bFGF and human epidermal growth factor EGF: The two genes of human basic fibroblast growth factor bFGF and human epidermal growth factor EGF are redesigned to form two designed genes of human basic fibroblast growth factor bFGF and human epidermal growth factor EGF respectively;

[0008] (2) Design and synthesis of gene fusion of human basic fibroblast growth factor bFGF and human epidermal growth factor EGF: The designed human basic fibroblast growth factor bFGF and human epidermal growth factor EGF genes are fused, and restriction sites are set to form a fusion sequence bFGF-Tev-EGF;

[0009] (3) Construction of recombinant baculovirus expressing bFGF-Tev-EGF: A recombinant baculovirus expressing bFGF-Tev-EGF was constructed using the fusion sequence bFGF-Tev-EGF;

[0010] (4) Expression of recombinant bFGF-Tev-EGF and protein purification: The recombinant baculovirus was introduced into silkworm culture cells and fifth-instar silkworm larvae to express the recombinant protein, and then the recombinant protein was purified and eluted. After enzyme digestion, the recombinant protein was purified and eluted to obtain human epidermal growth factor EGF and human basic fibroblast growth factor bFGF.

[0011] In the step (1), the gene sequences of the designed two genes, human basic fibroblast growth factor bFGF and human epidermal growth factor EGF, are SEQ ID NO.1 and SEQ ID NO.2 respectively.

[0012] In the step (2), a TEV restriction site is set after fusion, and BamHI and HindIII restriction endonuclease sites are added at both ends, respectively.

[0013] The sequence of the TEV restriction site is SEQ ID NO.3, which is GAAAACCTGTATTTTCAGGGC.

[0014] In the step (2), the gene sequence of the fusion sequence bFGF-Tev-EGF is SEQ ID NO.4.

[0015] The step (3) is specifically as follows: first, according to the Bac-to-Bac recombinant baculovirus expression system suitable for silkworms, the fusion sequence bFGF-Tev-EGF is cloned into the donor plasmid pFastBacHTb to generate the recombinant plasmid pFastBacHTb-bFGF-Tev-EGF, and then the recombinant plasmid is transformed into DH10BmBac bacterial competent cells containing BmNPV Bacmid, so that the bFGF-Tev-EGF gene is inserted into the Bacmid through the transposition of the transposon;

[0016] Then, the recombinant Bacmid was identified by blue-white screening on culture plates containing antibiotics such as anka penicillin and kanamycin. The recombinant Bacmid was further extracted and transfected into silkworm culture cells to produce recombinant baculovirus expressing bFGF-Tev-EGF.

[0017] In the step (4), human epidermal growth factor EGF and human basic fibroblast growth factor bFGF are purified in two steps by using heparin affinity chromatography and TEV enzyme cleavage.

[0018] The step (4) is specifically:

[0019] The recombinant baculovirus constructed above was inoculated into Bombyx mori cultured cells or fifth instar larvae of Bombyx mori, and cell samples were collected 96 hours after infection, and the expression level of recombinant bFGF-Tev-EGF was analyzed by SDS-PAGE electrophoresis;

[0020] The recombinant protein was further purified using a heparin affinity column (heparin sepharose). The recombinant protein was used as the target protein. The recombinant protein was eluted with an elution solution, and then TEV enzyme was added for enzymatic cleavage to separate bFGF and EGF. The protein was then passed through the heparin affinity column again, and the collected sample was a purified human epidermal growth factor EGF solution. The purified human basic fibroblast growth factor bFGF solution was obtained using the elution solution.

[0021] The purified solution is dialyzed and freeze-dried to obtain the pure product.

[0022] The elution solution is a 2.0 M NaCl solution.

[0023] The method of the invention utilizes the strong binding characteristics of human basic fibroblast growth factor (bFGF) and heparin, utilizes gene fusion and gene synthesis technology, and utilizes the codon preference of baculovirus-encoded proteins to re-optimize and design the two genes of bFGF and human epidermal growth factor (EGF), fuse the two genes, set a TEV restriction site in the middle, then utilize the silkworm baculovirus expression system to construct a recombinant baculovirus capable of expressing the fusion gene, express the bFGF-EGF fusion protein in silkworm cells and silkworms, and utilize a heparin affinity chromatography column to quickly separate and purify the protein, finally utilize TEV enzyme to separate the two, and realize effective separation of the two proteins after re-passing through the affinity chromatography column.

[0024] Compared with the prior art, the present invention has the following beneficial effects:

[0025] The present invention optimizes the design of bFGF and EGF, fuses the two genes by gene synthesis, and further constructs a recombinant baculovirus capable of simultaneously expressing bFGF and EGF by using the silkworm Bac-to-Bac baculovirus expression system. By infecting silkworm culture cells and fifth-instar silkworm larvae, the fusion protein is analyzed to have a high expression efficiency ( Figure 1 ), and is easy to purify quickly.

[0026] The scheme of the present invention has important reference significance for improving some recombinant proteins that are relatively difficult to purify, and has broad application prospects in the field of genetic engineering. BRIEF DESCRIPTION OF THE DRAWINGS

[0027] Figure 1 This is the SDS-PAGE analysis electrophoresis diagram of the expression level of the recombinant bFGF-EGF in Example 1.

[0028] Figure 2 The results of expression and purification of the recombinant bFGF and EGF in silkworm cells of Example 1 are shown. DETAILED DESCRIPTION

[0029] The present invention is further described in detail below with reference to the accompanying drawings and specific embodiments.

[0030] Embodiments of the present invention are as follows:

[0031] Example 1

[0032] (1) Re-optimization design of two genes, human basic fibroblast growth factor (bFGF) and human epidermal growth factor (EGF). In order to improve the expression level of foreign genes in silkworms, the codon preference principle of the polyhedrin gene, a gene expressed at a very high level in the late stage of silkworm baculovirus, was used (see Table 1):

[0033] Table 1. Analysis of codon preference of BmNPV polyhedrin

[0034]

[0035]

[0036] The bFGF and EGF genes were redesigned (see Table 2):

[0037] Table 2 Comparison of original sequences and optimized design sequences of bFGF and EGF

[0038]

[0039] (2) Design and synthesis of bFGF and EGF gene fusion. The design fuses the bFGF and EGF genes, sets a TEV restriction site in the middle (sequence: GAAAACCTGTATTTTCAGGGC), and adds BamHI and HindIII restriction endonuclease sites at both ends of the gene. The newly designed fusion sequence is shown in Table 3. This new DNA sequence is named bFGF-Tev-EGF and commissioned to be synthesized by a company.

[0040] Table 3 Newly designed bFGF-Tev-EGF fusion sequences

[0041]

[0042] Note: The middle underlined part represents the TEV restriction site sequence, and the last underlined TAA is the stop codon.

[0043] (3) Construction of recombinant baculovirus expressing bFGF-Tev-EGF: Based on the previously constructed Bac-to-Bac recombinant baculovirus expression system suitable for silkworms, the bFGF-Tev-EGF sequence digested with BamHI and HindIII was cloned into the donor plasmid pFastBacHTb to produce the recombinant plasmid pFastBacHTb-bFGF-Tev-EGF. The plasmid was then transformed into DH10BmBac bacterial competent cells containing BmNPV Bacmid. The bFGF-Tev-EGF gene was inserted into the Bacmid through the transposition of the transposon. The recombinant Bacmid was identified by blue-white screening on culture plates containing antibiotics such as anka penicillin and kanamycin. The recombinant Bacmid was further extracted and transfected into silkworm culture cells to produce recombinant baculovirus expressing bFGF-Tev-EGF.

[0044] (4) Expression analysis and protein purification of recombinant bFGF-Tev-EGF: The recombinant baculovirus constructed above was inoculated into Bombyx mori cultured cells or fifth-instar larvae of Bombyx mori, and cell samples were collected 96 hours after infection. The expression level of recombinant bFGF-Tev-EGF was analyzed by SDS-PAGE electrophoresis.

[0045] The results of SDS-PAGE analysis of the expression level of recombinant bFGF-EGF obtained in this example are as follows: Figure 1 As shown, Figure 1 Middle: The leftmost lane is the standard molecular weight; the middle lane is the control, that is, the cultured cells without recombinant baculovirus inoculation; the rightmost lane is the silkworm cultured cell sample infected with recombinant bFGF-EGF baculovirus. The predicted molecular weight of bFGF-EGF is 25.4KDa.

[0046] The recombinant protein was further purified using a heparin sepharose affinity column. The target protein was eluted with a 2.0M NaCl solution, and then TEV enzyme was added for enzymatic cleavage to separate bFGF and EGF. Then, the mixture was passed through the affinity column again. EGF could not bind to the affinity column and flowed out directly. The collected sample was purified EGF, while bFGF was bound to the affinity column and eluted with 2.0M NaCl to obtain purified bFGF. The purified sample was only dialyzed and freeze-dried to obtain the pure product.

[0047] The results of expression and purification of recombinant bFGF and EGF in silkworm cells obtained in this example are as follows: Figure 2 As shown, Figure 2 Middle: The left picture shows the results of bFGF purification, and the right picture shows the results of EGF purification. (bFGF predicted molecular weight 16.4KDa, EGF predicted molecular weight 6.4KDa).

[0048] It can be seen from this implementation that, compared with the currently published research results, the method of the present invention significantly improves the purification efficiency of recombinant proteins, greatly reduces the production costs of recombinant bFGF and EGF, and provides a significantly innovative technology for the large-scale production and medical application of recombinant bFGF and EGF.

[0049] The gene sequence involved in the present invention is as follows:

[0050] SEQ ID No.1;

[0051] Name: Designed DNA sequence of human basic fibroblast growth factor bFGF

[0052] DNA type: unassigned DNA

[0053] Biological source: Artificial sequence / synthetic construct

[0054] CCCGCCCTCCCCGAGGACGGCGGCAGCGGCGCCTTCCCCCCCGGCCACTTCAAAGACCCCAAACGCCTCTACTGCAAAAACGGCGGCTTCTTCCTCCGCATCCACCCCGACGGCCGCGTGGACGGCGTGCGCGAGAAAAGCGACCCCCACATCAAACTCCAACTCCAAGCCGAAGAGCGCGGCGTGGTGAGCATCAAAGGCGTGTGCGCCAACCGCTAC CTCGCCATGAAAGAAGACGGCCGCCTCCTCGCCTCTAAATGCGTGACCGACGAGTGCTTCTTTTTTGAACGCCTCGAAAGCAACAACTACAACACCTACCGCAGCCGCAAATACACCAGCTGGTACGTGGCCCTCAAACGCACCGGCCAATACAAACTCGGCAGCAAAACCGGCCCCGGCCAAAAAGCCATCCTCTTTCCCCCATGAGCGCCAAAAGC

[0055] SEQ ID No.2;

[0056] Name: Designed DNA sequence of human epidermal growth factor EGF

[0057] DNA type: unassigned DNA

[0058] Biological source: Artificial sequence / synthetic construct

[0059] AACAGCGACAGCGAGTGCCCCCTCAGCCACGACGGCTACTGCCTCCATGACGGCGTGTGCATGTACATCGAGGCCCTCGACAAATACGCCTGCAACTGCGTGGTGGGCTACATCGGCGAGCGCTGCCAATACCGCGACCTCAAATGGTGGGAGCTCCGCTAA

[0060] SEQ ID No.3;

[0061] Name: Sequence of TEV cleavage site

[0062] DNA type: unassigned DNA

[0063] Organism source: Artificial Sequence / synthetic construct

[0064] GAAAACCTGTATTTTCAGGGC

[0065] SEQ ID No.4;

[0066] Name: DNA sequence of the fusion sequence bFGF - Tev - EGF

[0067] DNA type: unassigned DNA

[0068] Organism source: Artificial Sequence / synthetic construct

[0069] CCCGCCTTGCCCGAGGATGGCGGCAGCGGCGCCTTCCCGCCCGGCCACTTCAAGGACCCCAAGCGGCTGTACTGCAAAAACGGGGGCTTCTTCCTGCGCATCCACCCCGACGGCCGAGTTGACGGGGTCCGGGAGAAGAGCGACCCTCACATCAAGCTACAACTTCAAGCAGAAGAGAGAGGAGTTGTGTCTATCAAAGGAGTGTGTGCTAACCGTTACCTGGCTATGAAGGAAGATGGAAGATTACTGGCTTCTAAATGTGTTACGGATGAGTGTTTCTTTTTTGAACGATTGGA

[0070] ATCTAATAACTACAATACTTACCGGTCAAGGAAATACACCAGTTGGTATG

[0071] TGGCACTGAAACGAACTGGGCAGTATAAACTTGGATCCAAAACAGGACC

[0072] TGGGCAGAAAGCTATACTTTTTCTTCCAATGTCTGCTAAGAGCGAAAACC

[0073] TGTATTTTCAGGGCAACAGCGACAGCGAGTGCCCCCTCAGCCACGACGGC

[0074] TACTGCCTCCATGACGGCGTGTGCATGTACATCGAGGCCCTCGACAAATA

[0075] CGCCTGCAACTGCGTGGTGGGCTACATCGGCGAGCGCTGCCAATACCGCG

[0076] ACCTCAAATGGTGGGAGCTCCGCTAA。

Claims

1. A method for simultaneously expressing bFGF and EGF in silkworms and facilitating rapid protein purification, characterized in that: The steps are as follows: (1) redesigning two genes, human basic fibroblast growth factor bFGF and human epidermal growth factor EGF, to form two designed genes, human basic fibroblast growth factor bFGF and human epidermal growth factor EGF, respectively; (2) fusing the designed human basic fibroblast growth factor bFGF and human epidermal growth factor EGF genes, and setting restriction sites to form a fusion sequence bFGF-Tev-EGF; (3) constructing a recombinant baculovirus expressing bFGF-Tev-EGF using the fusion sequence bFGF-Tev-EGF; (4) The recombinant baculovirus is introduced into silkworm culture cells and fifth-instar silkworm larvae to express the recombinant protein, and the recombinant protein is purified and eluted, and then digested by enzymes and purified and eluted to obtain human epidermal growth factor EGF and human basic fibroblast growth factor bFGF.

2. A method for simultaneously expressing bFGF and EGF in silkworms and facilitating rapid protein purification according to claim 1, characterized in that: In the step (1), the gene sequences of the designed two genes, human basic fibroblast growth factor bFGF and human epidermal growth factor EGF, are SEQ ID NO.1 and SEQ ID NO.2 respectively.

3. A method for simultaneously expressing bFGF and EGF in silkworms and facilitating rapid protein purification according to claim 1, characterized in that: In the step (2), a TEV restriction site is set after fusion, and BamHI and HindIII restriction endonuclease sites are added at both ends, respectively.

4. A method for simultaneously expressing bFGF and EGF in silkworms and facilitating rapid protein purification according to claim 3, characterized in that: The sequence of the TEV restriction site is SEQ ID NO.

3.

5. A method for simultaneously expressing bFGF and EGF in silkworms and facilitating rapid protein purification according to claim 1, characterized in that: In the step (2), the gene sequence of the fusion sequence bFGF-Tev-EGF is SEQ ID NO.

4.

6. A method for simultaneously expressing bFGF and EGF in silkworms and facilitating rapid protein purification according to claim 1, characterized in that: The step (3) is specifically: Firstly, according to the Bac-to-Bac recombinant baculovirus expression system of silkworm, the fusion sequence bFGF-Tev-EGF is cloned into the donor plasmid pFastBacHTb to produce the recombinant plasmid pFastBacHTb-bFGF-Tev-EGF, and then the recombinant plasmid is transformed into DH10BmBac bacterial competent cells containing BmNPV Bacmid, so that the bFGF-Tev-EGF gene is inserted into the Bacmid through the transposition of the transposon; then the recombinant Bacmid is identified by blue-white screening on an antibiotic culture plate, and the recombinant Bacmid is further extracted and transfected into the Bombyx mori culture cells to produce the recombinant baculovirus expressing bFGF-Tev-EGF.

7. A method for simultaneously expressing bFGF and EGF in silkworms and facilitating rapid protein purification according to claim 1, characterized in that: In the step (4), human epidermal growth factor EGF and human basic fibroblast growth factor bFGF are purified in two steps by using heparin affinity chromatography and TEV enzyme cleavage.

8. A method for simultaneously expressing bFGF and EGF in silkworms and facilitating rapid protein purification according to claim 1 or 7, characterized in that: The step (4) is specifically as follows: The recombinant baculovirus constructed as above was inoculated into silkworm culture cells or fifth-instar silkworm larvae, and cell samples were collected 96 hours after infection; the recombinant protein was further purified using a heparin affinity column, the recombinant protein was eluted with an elution solution, and then TEV enzyme was added for enzymatic cleavage, and then it was passed through the heparin affinity column again, and the collected sample was a purified human epidermal growth factor EGF solution, and the purified human basic fibroblast growth factor bFGF solution was obtained using the elution solution.

9. A method for simultaneously expressing bFGF and EGF in silkworms and facilitating rapid protein purification according to claim 8, characterized in that: The elution solution is a 2.0 M NaCl solution.